Literature DB >> 32221526

COVID-19 Outbreak and Inflammatory Bowel Disease Management: A Questionnaire Survey From Realistic Practice.

Xiaoyin Bai1, Hong Yang1, Jiaming Qian1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32221526      PMCID: PMC7184492          DOI: 10.1093/ecco-jcc/jjaa064

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


× No keyword cloud information.
Coronavirus disease 2019 [COVID-19] has swept Wuhan and other cities in China since January 2020.[1] Despite the preliminary victory of containing the infection following 2 months of effort in China, the pandemic has posed a challenge regarding the routine clinical attention to patients with chronic disease. Inflammatory bowel disease [IBD] is a chronic disease which requires elaborate management. Due to the relative low incidence and prevalence of IBD,[2] the limited number of specialists, and the individualised therapeutic approaches in our country, treatment recommendations still depend on the collaborative effort of experts in the high-volume hospitals. Nevertheless, given the severity of COVID-19, patients are adviseded to follow local primary physicians, which may result in unmet medical needs. In addition, most patients with IBD require glucocorticoids, immunomodulators, or biologic agents for a long time, which increases the likelihood of experiencing side effects and compromises the treatment outcome. Our team is located in a tertiary hospital in Beijing, and we provide follow-up service for more than 150 patients with IBD who mainly live in the northern part of China. Under the special conditions of the past 2 months, we have adopted new methods of communication for follow-up such as mobile communication applications, distance text consultation, hotline. and telehealth. Also, we have been referring patients with severe active IBD to local specialists through our professional network. In the past 2 months, we have sent out questionnaires to our patients through emails, mobile communication applications, and text messaging [approved by Ethics Committee of Peking Union Medical College Hospital] to monitor patients’ progress. We received 125 effective responses in total. Their demographic features and clinical information are listed in Table 1. Patients were classified into four levels of severity in previous followup: severe [22, 17.6%], moderate [32, 25.6%], mild [31, 24.8%], and in remission [40, 32.0%]. Over the period of COVID-19 outbreak, 18 [14.4%] patients reported exacerbation, 12 [9.6%] patients have improved, and 95 [76.0%] patients remained unchanged [details demonstrated in Supplement 1, available as Supplementary data at ECCO-JCC online]. A total of 88 [70.4%] patients stated that COVID-19 pandemic affcted their scheduled follow-up. Overall 64 [51.2%] patients attended consultations via mobile communication applications, six [4.8%] patients received follow-up online, six [4.8%] patients attended patient information webinar, and 16 [12.8%] patients visited outpatient clinics or emergency departments in non COVID-19 treating hospitals. Only one patient felt his/her medical need had not been met during this special period.
Table 1.

Characteristics of patients with IBD responding to the questionnaire.

Characteristicss of patients, n [%]125 [100%]
Gender
 Male77 [61.6%]
 Female48 [38.4%]
Age, median, yr [minmax]39 [18–74]
Time since diagnosis, median, yr [minmax]5.0 [0.25–36]
Education level
 University-educated97 [77.6%]
 Primary education28 [22.4%]
Habitat
 Urban93 [74.4%]
 Rural32 [25.6%]
Diagnosis
 Ulcerative colitis58 [46.4%]
 Crohn’s disease45 [36.0%]
 Inflammatory bowel disease unclassified22 [17.6%]

IBD,inflammatory bowel disease; yr, years; min, minimum; max, maximum.

Characteristics of patients with IBD responding to the questionnaire. IBD,inflammatory bowel disease; yr, years; min, minimum; max, maximum. COVID-19 outbreaks have occurred in countries with high morbidity from IBD, such as East Asia [Korea and Japan], Europe [Italy, Germany, Spain, and France], and North America [USA].[3] We hope our experience may provide an alternative to face-to-face consultation for reviewing patients with IBD in above-mentioned countries, as follows. Mobile communication applications, such as WeChat,[4] is an effective and individualised method of information exchange. It takes a serious amount of time to conduct consultation via the app, but this approach can cover fundamental follow-up questions and soothe panic. Internet-based services such as email and hotline communication may solve some non-urgent medical issues for patients. For general concerns of IBD patients, such as diet advice and relaxation techniques, webinar is an effective and efficient source to provide information to patients and primary health practitioners. Timely referral has to be reserved for certain cases.

Funding

No specific funding was received for this work.

Conflict of Interest

None to declare.

Author Contributions

XB: data collection and writing up of the first draft of the paper. HY: patient recruitment and data analysis. JQ: study design and reviewing the writing.
  4 in total

Review 1.  The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis.

Authors:  Xue Li; Peige Song; Jun Li; Yuchang Tao; Guowei Li; Xiumin Li; Zengli Yu
Journal:  Int J Environ Res Public Health       Date:  2017-02-28       Impact factor: 3.390

2.  Internet and WeChat used by patients with Crohn's disease in China: a multi-center questionnaire survey.

Authors:  Qiao Yu; Liyi Xu; Lili Li; Min Zhi; Yubei Gu; Xinying Wang; Hong Guo; Yue Li; Yihong Fan; Bolin Yang; Meng Xue; Minfang Lv; Dingting Xu; Hanyun Zhang; Yan Li; Yongmao Song; Qun Deng; Xiaoxu Huang; Jing Zhong; Wen Hu; Yimiao Zhu; Xiaoying Wang; Jianting Cai; Yan Chen
Journal:  BMC Gastroenterol       Date:  2019-06-20       Impact factor: 3.067

3.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 4.  World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).

Authors:  Catrin Sohrabi; Zaid Alsafi; Niamh O'Neill; Mehdi Khan; Ahmed Kerwan; Ahmed Al-Jabir; Christos Iosifidis; Riaz Agha
Journal:  Int J Surg       Date:  2020-02-26       Impact factor: 6.071

  4 in total
  6 in total

1.  Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre.

Authors:  Franco Scaldaferri; Daniela Pugliese; Giuseppe Privitera; Sara Onali; Loris Riccardo Lopetuso; Gianenrico Rizzatti; Carlo Romano Settanni; Marco Pizzoferrato; Elisa Schiavoni; Laura Turchini; Valeria Amatucci; Daniele Napolitano; Tiziana Bernabei; Vincenzina Mora; Lucrezia Laterza; Alfredo Papa; Luisa Guidi; Gian Lodovico Rapaccini; Antonio Gasbarrini; Alessandro Armuzzi
Journal:  United European Gastroenterol J       Date:  2020-05-21       Impact factor: 4.623

2.  COVID-19 pandemic and systemic autoinflammatory diseases management: a cross-sectional survey.

Authors:  Na Wu; Mengzhu Zhao; Di Wu; Keyi Yu; Min Shen
Journal:  Rheumatol Int       Date:  2021-04-12       Impact factor: 2.631

3.  COVID-19 quarantine measures are associated with negative social impacts and compromised follow-up care in patients with inflammatory bowel disease in Brazil.

Authors:  Marley Ribeiro Feitosa; Rogério Serafim Parra; Hugo Parra de Camargo; Sandro da Costa Ferreira; Luiz Ernesto de Almeida Troncon; José Joaquim Ribeiro da Rocha; Omar Féres
Journal:  Ann Gastroenterol       Date:  2020-11-26

Review 4.  Impact of COVID-19 pandemic on the healthcare and psychosocial well-being of patients with inflammatory bowel disease.

Authors:  Anna Theodorou-Kanakari; Paraskevas Gkolfakis; Georgios Tziatzios; Lazaros Dimitrios Lazaridis; Konstantinos Triantafyllou
Journal:  Ann Gastroenterol       Date:  2022-02-10

Review 5.  Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.

Authors:  Marko Kumric; Tina Ticinovic Kurir; Dinko Martinovic; Piero Marin Zivkovic; Josko Bozic
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

6.  Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China.

Authors:  Ying-Fan Zhang; Yun Qiu; Jin-Shen He; Jin-Yu Tan; Xiao-Zhi Li; Liang-Ru Zhu; Yan Chen; Zhan-Ju Liu; Marietta Iacucci; Bai-Li Chen; Yao He; Shomron Ben-Horin; Bo Shen; Zhi-Rong Zeng; Subrata Ghosh; Min-Hu Chen; Ren Mao
Journal:  J Gastroenterol Hepatol       Date:  2020-08-16       Impact factor: 4.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.